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Advances in breast cancer control will be greatly aided by early detection so as to diagnose and treat breast cancer in its preinvasive
state prior to metastasis. For breast cancer, the second leading cause of cancer-related death among women in the United States,
early detection does allow for increased treatment options, including surgical resection, with a corresponding better patient
response. Unfortunately, however, many patients’ tumors are diagnosed following metastasis, thus making it more diﬃcult to
successfully treat the malignancy. There are, at present, no existing validated plasma/serum biomarkers for breast cancer. Only
a few biomarkers (such as HER-2/neu, estrogen receptor, and progesterone receptor) have utility for diagnosis and prognosis.
Thus, there is a great need for new biomarkers for breast cancer. This paper will focus on the identiﬁcation of new serum protein
biomarkers with utility for the early detection of breast cancer.
1.Introduction
Advancesinbreastcancercontrolwillbegreatlyaidedbyear-
ly detection, thereby facilitating diagnosis and treatment of
breast cancer in its preinvasive state prior to metastasis.
Breast cancer is the most frequently occurring malignancy
and the second leading cause of cancer-related death for
women in the United States [1]. The most eﬃcacious screen-
ing modality utilized in the clinic is mammography though
lesions less than 0.5cm in size remain undetectable by
present technology. Importantly, however, even though a
breast lesion may be detected, given the low sensitivity/spec-
iﬁcity of mammography, approximately 4-fold more women
(than those with breast malignancies) have resultant biop-
sies. Five-year survival of women with breast cancer is high-
ly correlated with tumor stage, with tumor detection at very
early stages (stages 0 and I) having an approximate 98%
5-year survival. Five-year survival for stage II tumors is
approximately 85%, stage III approximately 60%, and stage
IVapproximately20%.Overall,breastcancerhasanapproxi-
mate80%5-yearsurvival,with207,090newcasesand39,840
deaths expected in women in the United States in 2010 [1].
Early detection of breast cancer does allow for increased
treatment options, including surgical resection, with a cor-
responding better patient response. Surgical resection may
involve lumpectomy or mastectomy with removal of some
of the axillary lymph nodes. Following early detection, radi-
ation therapy, chemotherapy (before or after surgery), and
hormone therapy (tamoxifen [2] and aromatase inhibitors
[3–5]) also have utility for therapeutic intervention. Targeted
biologic therapy with trastuzumab (Herceptin) [6] or lapa-
tinib (Tykerb) [7, 8] also has utility to treat HER2/neu-pos-
itivebreasttumors.Unfortunately,however,intheabsenceof
good serum/plasma biomarkers many breast cancer patients
are diagnosed too late in the disease process (i.e., after the
tumors metastasize) for surgical resection to be an eﬀective
option. Thus, these patients are typically oﬀered various
therapeutic treatment modalities dependent upon tumor
subtype (ER+ or ER−;H E R 2 + or HER2−). The available
treatment modalities may include hormonal (antiestrogen),
taxane (docetaxel or paclitaxel) or nontaxane chemotherapy.
Ingeneral,womenwithmetastaticbreastcancerareprovided
onetherapeuticmodalityuntiltreatmentfailureandarethen
switched to another therapeutic modality.
The origin of most breast cancer cases is not known.
However, many risk factors have been identiﬁed, including
female gender, increasing patient age, family history of breast2 International Journal of Proteomics
cancer at an early age, early menarche, late menopause, older
maternal age at ﬁrst live childbirth, prolonged hormone re-
placementtherapy, exposure to therapeutic chestirradiation,
benign proliferative breast disease, and genetic mutations in
g e n e ss u c ha sB R C A 1 / 2[ 9]. The overwhelming majority of
breast masses detected by palpation and/or by mammogra-
phy are epithelial lesions, which include benign ﬁbrocystic
change,hyperplasia,carcinomainsitu,andinﬁltratingmam-
mary carcinoma. Although several histologic types and sub-
types of mammary carcinomas exist, >95% are either ductal
or lobular carcinomas [10], with the majority (75%–80%) of
mammary carcinomas being ductal carcinomas [11, 12].
A number of genetic alterations have been identiﬁed in
breast tumors. The most frequent genomic aberrations iden-
tiﬁed are gains along chromosomes 1q, 8q, 17q, 20q, and
11q and losses along 8p, 13q, 16q, 18q, and 11q [13–18].
Interestingly, many of these chromosomal segments harbor
known proto-oncogenes and/or tumor suppressor genes
such as BRCA1, BRCA2, HER2-neu, C-MYC, and Cyclin D-
1. Low-grade (grade 1) inﬁltrating ductal carcinomas have
relatively few numbers of chromosomal alterations with the
highest frequency of aberrations occurring as losses on 16q
and gains on 1q.
It is generally accepted that estrogen receptor-positive
(ER+)andER-negative(ER−)breastcancersaretwodiﬀerent
disease entities. ER− tumors tend to be of high grade, have
more frequent p53 mutations, and have worse prognosis
compared with ER+ disease. Both ER+ and ER− tumors can
b ee i t h e rH E R 2p o s i t i v eo rn e g a t i v e .L o w - g r a d et u m o r sa r e
typically ER positive, almost always HER2 nonampliﬁed,
and frequently overexpress cyclin D-1 [10]. In contrast,
high-grade (grade 3) tumors tend to be ER negative, have
frequent loss of p53 function, usually overexpress C-MYC
and commonly overexpress HER2 [13–15, 19]. In the high-
grade tumors, loss of p53 function is usually due to 17p13
deletion, mutation or inactivation, while overexpression of
HER2 is usually because of 17q12 ampliﬁcation [20–28].
Although early detection of cancer has improved survival
for a number of cancers, including breast cancer [29], colon
cancer [30–32], prostate cancer [33, 34], and cervical cancer
[35], existing serum biomarkers for breast cancer are not
adequate for early detection. The possibility of early detec-
tion of breast cancer may be realized through both noninva-
sive (i.e., imaging technologies) and invasive means (patient
serum proﬁling). To date, gains in the early detection of
breast cancer have been largely made due to routine mam-
mography and/or by palpation (either self-examination or
by physician or nurse practitioner). Imaging technologies
(mammography, digital mammography, and magnetic reso-
nance imaging (MRI)) have been adopted clinically for mass
screening purposes, but there is resistance for seeking such
services on a yearly basis, given the relative complexity and
high cost-to-beneﬁt ratio of these imaging methodologies.
As a result, there has been much interest in development and
validationofserum-basedbiomarkersfortheearlydetection,
risk stratiﬁcation, prediction, and disease prognosis of breast
cancer.Thispaperwillfocusonrecentdevelopmentsiniden-
tiﬁcation of new serum protein biomarkers with potential
utility for the early detection of breast cancer (Table 1).
2.AutoantibodiesandBreast Cancer
The humoral immune response to cancer in humans has
been well demonstrated by identiﬁcation of autoantibodies
to a number of diﬀerent intracellular and surface antigens in
patients with various tumor types [36–39]. A tumor-speciﬁc
humoral immune response directed against oncoproteins
[40, 41], mutated proteins such as p53 [42, 43], or other
aberrantly expressed proteins have all been described. While
it is currently unknown whether the occurrence of such anti-
bodies is beneﬁcial, knowledge of potential tumor antigens
that may evoke tumor-speciﬁc immune responses may have
utilityinearlycancerdiagnosis,inestablishingprognosisand
in immunotherapy against the disease.
Several approaches are currently available for the iden-
tiﬁcation of tumor antigens. In contrast to identiﬁcation of
tumor antigens based on analysis of recombinant proteins
(which do not contain posttranslational modiﬁcations as
found in tumors or tumor cell lines), it may be preferable
to utilize a proteomics-based approach for the identiﬁcation
of tumor antigens. This may facilitate the identiﬁcation of
autoantibodies to naturally occurring proteins, such as in
lysates prepared from tumors and tumor cell lines, and may
uncover antigenicity associated with aberrant posttransla-
tionalmodiﬁcationoftumorcellproteins.Suchaproteomics
approach was implemented for the identiﬁcation of breast
tumor antigens that elicit a humoral response against pro-
teins that are expressed in the SUM-44 breast cancer cell line.
2D PAGE was used to simultaneously separate individual
cellular proteins from the SUM-44 cell line. The separated
proteins were transferred onto PVDF membranes. Sera from
breast cancer patients were screened individually for anti-
bodies that reacted against the separated proteins by Western
blot analysis. Proteins speciﬁcally reacting with sera from the
breast cancer patients were identiﬁed by mass spectrometry.
Le Naour and colleagues [36] have shown that a humoral
response directed against RS/DJ-1 occurred in 13.3% of
newly diagnosed breast cancer patients. None of the 25
healthy controls (0%) or 46 patients (0%) with hepatocel-
lular carcinoma exhibited autoantibodies to RS/DJ-1. Only
2/54 (3.7%) samples of sera from lung adenocarcinoma
patients demonstrated autoantibodies to RS/DJ-1.
Inbreastcancer,besidesRS/DJ-1[36],autoimmunityhas
also been shown against a number of other cellular proteins.
These proteins include p53 [44–47], heat shock protein 60
[48, 49], heat shock protein 90 [50, 51], and mucin-related
antigens [49, 52–54]. The presence of p53 autoantibodies
have been observed in 15% of patients with breast cancer
and were shown to be associated with a poor prognosis
[44, 45, 47]. However, p53 autoantibodies have also been
found in patients with other malignancies and inﬂammatory
conditions [42, 43], thus the humoral response to p53 is not
speciﬁc to breast cancer. A humoral response to the 90kDa
heat shock protein has also been associated with poor sur-
vivalinbreastcancer[51].Incontrast,thepresenceofMUC1International Journal of Proteomics 3
Table 1: Current promising biomarkers for the detection of breast cancer.
Name of biomarker Technology used for discovery Type Reference
RS/DJ-1 Humoral response autoantibody [36]
p53 Humoral response autoantibody [44–47]
HSP60 Humoral response autoantibody [48, 49]
HSP90 Humoral response autoantibody [50, 51]
Mucin-related Humoral response autoantibody [49, 52–54]
CA 15-3 Serum proﬁling serum protein [55, 56]
RS/DJ-1 Serum proﬁling serum protein [36]
HER-2/neu Serum proﬁling serum protein [72]
α-2-HS-glycoprotein Nipple aspirate ﬂuid proﬁling Ductal protein [90]
Lipophilin B Nipple aspirate ﬂuid proﬁling Ductal protein [90]
beta-globin Nipple aspirate ﬂuid proﬁling Ductal protein [90]
Hemopexin Nipple aspirate ﬂuid proﬁling Ductal protein [90]
Vitamin D-binding protein Nipple Aspirate Fluid Proﬁling Ductal protein [90]
autoantibodies has been associated with a reduced risk for
disease progression in patients with breast cancer [53, 54].
While the antigenic epitope on MUC1 (or, for that matter,
any of the other breast tumor antigens discussed above) is
unknown, MUC1 has been shown to be aberrantly glyco-
sylated frequently in breast cancer [54]. At present, CA 15-
3 (a soluble or secreted form of MUC1) has utility as a
circulating marker for breast cancer [55, 56]. Serial mea-
surements of CA 15-3 have utility to detect recurrences
and to monitor the treatment of metastatic breast cancer
[55–57]. Additionally, the CA 15-3 concentration at initial
presentation does have prognostic signiﬁcance [58–62].
I no r d e rt oc i r c u m v e n tm a n yo ft h ed i ﬃculties associ-
ated with 2D-PAGE (namely, inadequate resolution, slow
throughput, and limited dynamic range), protein microar-
rays were developed that have the capability to screen pa-
tient’s sera for autoantibodies directed against tumor anti-
gens [63–66]. In comparison to traditional ELISAs that use
single puriﬁed recombinant proteins, the protein microar-
rays are capable of presenting and analyzing >1000 tumor
antigenssimultaneously.Inaddition,asthesetumorantigens
are typically derived from diseased tissues or disease-related
cells, they possess disease-related, potentially antigenic, post-
translational modiﬁcations not normally expressed by the
particular cells or tissue. In this technology, proteins from
diseased tissues or disease-related cell lines are separated
by2-dimensionalliquidchromatography(chromatofocusing
or ion exchange HPLC in the ﬁrst dimension, followed by
reverse phase HPLC in the second dimension). Following
separation, all fractions (≥1700 fractions) from each sep-
aration are printed onto nitrocellulose-coated microscope
slides and are subsequently probed with sera from patients
or control subjects [63–66]. As each reactive fraction may
contain a number of diﬀerent proteins, each reactive fraction
would need to be further assessed to determine the tumor
antigen of interest.
More recently, Ramachandran et al. [67, 68] developed
a novel protein microarray technology, termed nucleic acid
p r o t e i np r o g r a m m a b l ea r r a y( N A P P A ) .N A P P Aa r r a y sa r e
generated by printing full-length cDNA encoding the target
proteins at each feature of the array. The proteins are then
transcribed and translated by a cell-free system and immobi-
lizedinsituusingepitopetagsfusedtotheproteins.Although
this technology circumvents many of the diﬃculties of tra-
ditional protein microarrays (i.e., the need to resolve com-
plex protein lysates), the printed proteins on the array lack
all normal posttranslational modiﬁcations. Thus, any anti-
genicity resulting from aberrant modiﬁcation of tumor pro-
teins is not assessed. Anderson and colleagues [69] utilized
the NAPPA arrays to screen 4988 candidate tumor antigens
with sera from patients with early stage breast cancer for
autoantibodies. Twenty-eight of these antigens were con-
ﬁrmed using an independent serum cohort (n = 51 cases/38
controls,P<0.05).Usingall28antigens,aclassiﬁerwasiden-
tiﬁed with a sensitivity of 80.8% and a speciﬁcity of 61.6%
(AUC = 0.756). Although the sensitivity and speciﬁcity are
not high, these 28 recombinant protein antigens may be
considered as potential biomarkers for the early detection of
breast cancer.
It is not clear why only a subset of patients with a par-
ticular tumor type develop a humoral response to particular
tumor antigens. Immunogenicity may depend on the level
of expression, posttranslational modiﬁcation, or other types
of protein processing, the extent of which may be variable
among tumors of a similar histological type. Other factors
that may inﬂuence the immune response include variability
among tumors and individuals in major histocompatibility
complex molecules and in antigen presentation. Although
a number of autoantibodies have been identiﬁed in breast
cancer, in most cases, they occur in less than 50% of patient’s
sera. Therefore, they are not likely to be eﬀective individually
for the early detection of breast cancer but may show eﬃcacy
if utilized as a panel of biomarkers.
3. Detectionof AlteredPlasmaProtein
Expression for Identiﬁcation of Breast
Cancer-SpeciﬁcBiomarkers
There has been great interest in the hypothesis that tumor-
speciﬁc proteins may be found in patient’s circulation, and4 International Journal of Proteomics
they may have utility for the early detection of cancer. For
example, proteins such as CA125 in ovarian cancer and
prostate-speciﬁc antigen (PSA) in prostate cancer have been
used clinically as diagnostic markers of cancer. CA125 is a
mucin commonly employed as a diagnostic marker for
epithelial ovarian cancer. PSA is secreted primarily by pros-
tate epithelial cells into the seminal plasma and is one of the
best characterized examples of a secreted glycoprotein used
in cancer diagnostics.
There are a number of reports that have described aber-
rantly expressed proteins in the serum of breast cancer
patients. The most widely used serum marker in breast can-
cer diagnostics is CA 15-3, which detects soluble forms of the
mucin MUC1. MUC1 is normally found in the apical mem-
brane of normal secretory epithelium. Following malignant
transformation, however, MUC1 may be localized through-
out the external surface of the entire plasma membrane. In
addition,changesinMUC1glycosylationhavebeenreported
during neoplastic transformation [70, 71]. Although MUC1
is expressed in normal and neoplastic breast epithelium,
the clinical utility of MUC1 measurements is conﬁned to
measurements of shed or soluble forms (termed CA 15-3),
released from the cell surface by proteolytic cleavage. Unfor-
tunately, CA 15-3 is not suitable for early detection, as serum
levels are rarely increased in patients with early or localized
breast cancer. The main utility for CA 15-3 is for monitoring
therapy in patients with metastatic breast cancer.
Le Naour and coworkers [36]h a v ee v a l u a t e dR S / D J - 1
as a serum biomarker of breast cancer. In normal tissue,
expression of RS/DJ-1 was observed in epithelium, smooth
muscle, blood vessels, and nerves. All 15 (100%) invasive
ductal carcinomas and 3 (100%) invasive lobular carcinomas
showed some level of cytoplasmic and nuclear reactivity in
the neoplastic cells. Signiﬁcantly elevated levels of serum
RS/DJ-1 was observed in the sera of 11/30 patients with
newly diagnosed breast cancer, as compared to serum from
25 healthy subjects. However, these authors did not evaluate
serum RS/DJ-1 levels in patients with other types of breast
lesions. Thus, it is unknown whether the increased serum
RS/DJ-1 levels are cancer-speciﬁc.
In another study [72], signiﬁcantly higher serum HER-
2/neulevelswerefoundinpatientswithtissueoverexpression
of HER-2/neu. Univariate analysis showed that HER-2/neu
serum levels were prognostic factors in disease-free survival
and overall survival only in patients with tissue overexpres-
sion. When only patients with HER-2/neu overexpression
in tissue were studied, tumor size, nodal involvement, and
tumor markers (at least one positive) were found to be in-
dependent prognostic factors for both disease-free survival
and overall survival.
4.Use ofMassSpectrometricMethodologies
for Identiﬁcation of Breast Cancer-Speciﬁc
Biomarkers
Methodologies have been developed to directly analyze the
proteins contained within complex protein mixtures, such as
that found within human bioﬂuids (plasma or serum, nipple
aspirate ﬂuid, ductal lavage ﬂuid, saliva, etc.). Among these
technologies, some, like SELDI (Surface-Enhanced Laser
Desorption and Ionization) are mass spectrometry-based.
A number of investigators have used SELDI-TOF mass spec-
trometry to interrogate serum [73–81] and nipple aspirate/
ductal lavage ﬂuid [82–89] from patients with breast cancer.
In one study, serum samples from women with or without
breast cancer were analyzed using SELDI protein chip mass
spectrometry [77]. Using a case-control study design, serum
samplesfrom48femalepatientswithprimaryinvasivebreast
cancer were compared with samples from 48 age- and sex-
matched healthy controls. To increase the number of iden-
tiﬁable proteins, patient’s serum was proﬁled on IMAC30
(activated with nickel) ProteinChip surfaces. Diﬀerences in
protein intensity between breast cancer cases and controls
weremeasuredbytheMann-WhitneyU testandadjustedfor
confounding variables in a multivariate logistic regression
model. Three peaks, with mass-to-charge ratio (m/z) 4276,
4292 and 8941 were found that showed signiﬁcant decreased
expression in cancer sera, as compared to control sera (P <
0.001). One drawback of the SELDI technology, however, is
thatgiventhelimiteddynamicrangeofSELDI,itislikelythat
distinctive features observed in serum with this approach
representrelativelyabundantproteinsthatarenotnecessarily
speciﬁc to breast cancer. Further, SELDI has diﬃculties in
providing the identiﬁcation of the distinctive proteins when
used to directly proﬁle complex protein mixtures.
5. Mass-Spectrometric Proﬁlingof Nipple
AspirateFluid orDuctal LavageFluid
Other mass spectrometric proﬁling methods have been
utilized to proﬁle proteins found in nipple aspirate ﬂuid [90]
a n dd u c t a ll a v a g eﬂ u i di no r d e rt oi d e n t i f yb r e a s tc a n c e r -
speciﬁc biomarkers. These investigators [90]a n a l y z e dp a i r e d
nipple aspirate ﬂuid samples from 18 women with stage I
or stage II unilateral invasive breast cancer and 4 healthy
volunteers using ICAT (isotope-coded aﬃnity tag) labeling,
followed by SDS-PAGE. Gel slices were cut from each sam-
ple, with subsequent analysis by liquid chromatography tan-
dem mass spectrometry (LC-MS/MS). They identiﬁed 353
peptides from the tandem mass spectra. Alpha-2-HS-gly-
coprotein was found to be underexpressed in nipple aspirate
ﬂuid from tumor-bearing breasts, while lipophilin B, beta-
globin, hemopexin and vitamin D-binding protein were all
overexpressed. Unfortunately, these authors only identiﬁed
abundant proteins whose over- or underexpression was
somewhat modest. Moreover, these authors did not analyze
nipple aspirate ﬂuid from patients with inﬂammatory breast
disease. Thus, conclusions cannot be drawn regarding breast
cancerspeciﬁcity of protein expression.
6. N-linked Glycan Proﬁlingfor Biomarker
Identiﬁcation in Breast Cancer Serum
Glycoproteins are the most heterogeneous group of post-
translational modiﬁcations known in proteins. Glycans show
a high structural diversity reﬂecting inherent functionalInternational Journal of Proteomics 5
diversity. N- and O-oligosaccharide variants on glycopro-
teins (glycoforms) can lead to alterations in protein activity
or function that may manifest itself as overt disease [91, 92].
Many clinical biomarkers and therapeutic targets in cancer
are glycoproteins [93–95], such as CA125 in ovarian cancer,
HER2/neu in breast cancer, and prostate-speciﬁc antigen
(PSA) in prostate cancer. The human epidermal growth
factor receptor 2 (HER2/neu) is a transmembrane glycopro-
tein, where the presence of HER2 overexpression appears
to be a key factor in malignant transformation and is pre-
dictiveofapoorprognosisinbreastcancer.CA125isamucin
commonly employed as a diagnostic marker for epithelial
ovarian cancer. Although CA125 has been used as an ovarian
cancer marker for a long time, many of its O- and N-glycan
structures have only recently been characterized [96]. PSA is
secretedprimarilybyprostateepithelialcellsintotheseminal
plasma. It is one of the best characterized examples of a
secreted glycoprotein used in cancer diagnostics, and its gly-
coforms have been described [97] .T h ea l t e r a t i o ni np r o t e i n
glycosylation that occurs through varying the heterogeneity
ofglycosylationsitesorchangingglycanstructureofproteins
on the cell surface and in body ﬂuids has been shown to
correlate with the development or progression of cancer and
other disease states [98]. It has been reported that the gly-
cosylation of PSA secreted by the tumor prostate cell line
LNCaP diﬀers signiﬁcantly from that of PSA from seminal
plasma (normal control). These carbohydrate diﬀerences
allowadistinctiontobemadebetweenPSAfromnormaland
tumor origins and provide a valuable biochemical tool for
diagnosis of prostate cancer [99].
There is growing evidence that glycan structures on
glycoproteinsaremodiﬁedinbreastcancer[100–109].Breast
cancer-associated alterations have been demonstrated for
fucosylation groups and for sialylations on the plasma pro-
tein α-1-proteinase inhibitor [106]. Increased GlcNAc β1-
6Man α1-6Man β-branching in asparagine-linked oligosac-
charides has been observed in human tumor cells. The levels
of the β1-6 branched oligosaccharides were evaluated in
a series of benign and malignant human breast biopsies.
Normal human breast tissue and benign lesions showed low
expression but 50% of the primary malignancies examined
showed signiﬁcantly elevated β1-6 branching [107]. Sub-
sequently, L-PHA (a lectin that binds speciﬁcally to the
β1-6 branched oligosaccharides) lectin histochemistry was
performed on paraﬃn sections of human breast tissues.
All breast carcinomas and epithelial hyperplasia with atypia
demonstrated signiﬁcantly increased L-PHA staining as
compared to ﬁbroadenomas and hyperplasia without atypia
[108]. More recently, L-PHA reactive glycoproteins were
identiﬁed from matched normal (nondiseased) and malig-
nant tissue isolated from patients with invasive ductal breast
carcinoma [109]. Comparison analysis of the data identiﬁed
34 proteins that were enriched by L-PHA fractionation
in tumor relative to normal tissue for at least 2 cases of
ductal invasive breast carcinoma. Of these 34 L-PHA tumor
enriched proteins, 12 were common to all 4 matched cases
analyzed.
Abd Hamid and coworkers [110] analyzed ﬂuorescently
tagged serum N-glycans of advanced breast cancer patients
using exoglycosidases and LC-MS/MS. They found that the
expression of a trisialylated triantennary glycan containing
anα-1,3-linkedfucosewasincreasedinthepresenceofbreast
cancer. Kyselova and coworkers. proﬁled the permethylated
N-glycans in sera of breast cancer patients at diﬀerent
stages (stages I to IV) using MALDI TOF/TOF MS in one
study [111]. In a second study, they proﬁled reduced and
methylated serum N-glycans of late-stage breast cancer
patients using nanoliquid chromatography (LC) chip/time-
of-ﬂight (TOF) MS [112]. In both studies, they found an
increase in fucosylation in both core and branched segments
of N-glycans in the presence of breast cancer. In the latter
study, they found a decrease in expression of a biantennary-
monosialylated N-linked glycan and an increase in expres-
sion of a fucosylated triantennary-trisialylated N-linked
glycan in the presence of Stage IV breast cancer. These gly-
cosylation changes in a tumor-secreted protein may reﬂect
fundamental activity changes in the enzymes involved in
the glycosylation pathway, either through altered levels of
enzymes or altered enzymatic activity. Importantly, the
changes in glycan structure may serve as early detection
biomarkers of breast cancer.
7. Summary
Early detection of breast cancer, so as to diagnose and treat
cancer in its preinvasive state prior to metastasis, may greatly
impact the treatment and prognosis of patients with this
common, but deadly, malignancy. Unfortunately, at present,
suitable biomarkers have not been identiﬁed for the early
detection of breast cancer. Biomarker discovery for this
disease is still very much in its discovery phase. Multiple
approaches have been developed, as described above, that
hold promise for the identiﬁcation of serum biomarkers.
The protein biomarkers that have been identiﬁed to date do
not possess the requisite sensitivity/speciﬁcity to have utility
individually as a biomarker for the early detection of breast
cancer but ultimately may have utility within a panel of pro-
tein biomarkers. Additionally, other emerging technologies,
suchasgeneticallyengineeredmousemodelsofbreastcancer
may have utility to identify panels of serum biomarkers
that can be further explored in human sera. In order to
determine the utility of any promising protein biomarkers,
the candidates will need to be tested and validated by
multiple independent studies using an adequately sized
test and training set of sera samples from very early-stage
breast cancer. Development of such resources, including
serum from patients with nonmalignant breast lesions and
prospective serum collection from individuals at high risk
of being diagnosed with breast cancer as well as serum from
patientswithotherbreastlesionsandothertypes(nonbreast)
of malignancies is of critical need for the identiﬁcation of
biomarkers with utility for the early detection of breast can-
cer. Up until now, serum/plasma collection has been pri-
marily performed in individual laboratories, using hetero-
geneous sample collection methods. The Human Proteome
Organization (HUPO) has conducted a study to assess ef-
ﬁcacious serum collection methods. These ﬁndings have6 International Journal of Proteomics
lead to eﬀorts presently being made by the National Cancer
Institute, through the Early Detection Research Network,
to develop suitable serum resources for both the discovery
phase and the subsequent validation phase of biomarkers for
the early detection of cancer. With the ultimate development
of these standardized resources, it is expected that suitable
biomarkers would be validated and have utility for the early
clinical detection of breast cancer within the next ﬁve-to-ten
years.
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